MARKET

INMB

INMB

Inmune Bio Inc
NASDAQ
7.62
-0.14
-1.80%
Opening 14:09 05/05 EDT
OPEN
7.76
PREV CLOSE
7.76
HIGH
7.76
LOW
7.40
VOLUME
90.41K
TURNOVER
--
52 WEEK HIGH
12.72
52 WEEK LOW
4.320
MARKET CAP
175.14M
P/E (TTM)
-3.6114
1D
5D
1M
3M
1Y
5Y
1D
INmune Bio Inc <INMB.OQ> expected to post a loss of 47 cents a share - Earnings Preview
Reuters · 6h ago
INMUNE BIO INC. TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON THURSDAY, MAY 8TH
Reuters · 7h ago
Weekly Report: what happened at INMB last week (0421-0425)?
Weekly Report · 04/28 12:33
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/22 09:30
Pz-Cel Has Massive Potential For RDEB Patients
Seeking Alpha · 04/21 14:00
Weekly Report: what happened at INMB last week (0414-0418)?
Weekly Report · 04/21 12:32
Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™
TipRanks · 04/16 20:31
INmune Bio receives favorable patentability opinion for CORDStrom platform
TipRanks · 04/16 11:13
More
About INMB
More
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Recently
Symbol
Price
%Change

Webull offers INmune Bio Inc stock information, including NASDAQ: INMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INMB stock methods without spending real money on the virtual paper trading platform.